Deferasirox - Isotope Labelled Standards
References
FAQ's
References
- Lattmann, Rene; Acklin, Pierre, Substituted 3,5-Diphenyl-1,2,4-Triazoles And Their Use As Pharmaceutical Metal Chelators, Novartis A-G., Switzerland, EP914118B1, October 23, 2002
- Kaja, Ravi Kiran; Surendranath, K. V.; Radhakrishnanand, P.; Satish, J.; Satyanarayana, P. V. V., A stability indicating LC method for deferasirox in bulk drugs and pharmaceutical dosage forms, Chromatographia, Volume: 72, Issue: 5/6, Pages: 441-446, 2010
Frequently Asked Questions
What are the sources of Deferasirox impurities?
Impurities in Deferasirox can originate from starting materials, intermediates, reagents, solvents, or degradation of the active ingredient during storage or manufacturing processes.
How do Deferasirox impurities affect its stability and shelf life?
Impurities in Deferasirox can contribute to its degradation and reduce its stability over time. Therefore, monitoring and controlling impurity levels are crucial to maintaining the drug's stability and extending its shelf life.
Which solvent helps in the analysis of Deferasirox impurities?
DCM or DMSO are the solvents used for analyzing many impurities in Deferasirox.
What are the temperature conditions required to store Deferasirox impurities?
Deferasirox impurities are stored at a controlled room temperature between 2-8 °C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.